A review of in vitro and in vivo models of oesophageal and gastric cancer

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55(2):74-108
   PubMed Web of Science ®Google Scholar
• Khushalani NI. Cancer of the Esophagus and Stomach. Mayo Clin Proc 2008;83(6):712-22
   PubMed Web of Science ®Google Scholar
• Mudan SS, Kang JY. Epidemiology and clinical presentation in esophageal cancer. Carcinoma of the Esophagus. Cambridge University Press; 2008
   Google Scholar
• Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97(2):142-6
   PubMed Web of Science ®Google Scholar
• Devesa SS, Fraumeni JF Jr. The rising incidence of gastric cardia cancer. J Natl Cancer Inst 1999;1(9):747-94
   Google Scholar
• Abnet CC, Freedman ND, Hollenceck AR, A prospective study of BMI and risk of esophageal and gastric adenocarcinoma. Eur J Cancer 2008;44:465-71
   PubMed Web of Science ®Google Scholar
• Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49
   PubMedGoogle Scholar
• Guildford P, Hopkins J, Harraway J, E-cadherin germline mutations in familial gastric cancer. Nature 1998;392(6674):402-5
   PubMed Web of Science ®Google Scholar
• Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37
   PubMed Web of Science ®Google Scholar
• Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-33
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355(1):11-20
   PubMed Web of Science ®Google Scholar
• Bedenne L, Michel P, Bouche O, Chemoradiation followed by surgery compared to chemo-radiation alone in locally advanced operable thoracic esophageal cancer: A randomized multicentric phase III trial (FFCD 9102). J Clin Oncol 2007;25:1160-8
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
   PubMed Web of Science ®Google Scholar
• Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2(2):98-107
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotney W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Enlg J med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355(24):2542-50
   Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kang Y, Chung H, efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. J Clin Oncol 2009;27(18S): abstract LBA4509
   Google Scholar
• Available from: http://public.ukcrn.org.uk/search/Portfolio.aspx?Level1=1&Level2=16
   Google Scholar
• Nishihira T, Kasai M, Mori S, Characteristics of two cell lines (TE-1 and TE-2) derived from human squamous cell carcinoma of the esophagus. Gann 1979;70:575-84
   PubMedGoogle Scholar
• Kuriya Y, Kitamura M, Akaishi T, A new cell line (TE-3) derived from human squamous cell carcinoma of the esophagus. Tohoku J Exp Med 1983;139:377-87
   PubMed Web of Science ®Google Scholar
• Nishihira T, Hashimoto Y, Katayama M, Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993;119:441-9
   PubMed Web of Science ®Google Scholar
• Boonstra JJ, van der Velden AW, Beerend ECW, Mistaken Identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res 2007;67(17):7996-8001
   PubMed Web of Science ®Google Scholar
• Hector A, Koorstra JB, Hong SM, Establishment and characterization of a bona fide barrett esophagus-associated adenocarcinoma cell line. Cancer Bio Ther 2008;7(11):1753-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.sanger.ac.uk/genetics/CGP/CellLines
   Google Scholar
• Jaiswal KR, Morales CP, Feagins LA, Characterization of telomerase-immortalized, non-neoplastic, human bArrett's cell line (BAR-T). Dis Esophagus 2007;20:256-264
   PubMed Web of Science ®Google Scholar
• McCabe ML, Dlamini Z. The molecular mechanisms of oesophageal cancer. In Immunopharmacol 2005;5:1113-30
   PubMed Web of Science ®Google Scholar
• Okawa T, Michaylira CZ, Kalabis J, The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev 2007;21(21): 2788-803
   PubMed Web of Science ®Google Scholar
• Maters JRW, Palsson B. Cancer Cell Lines. Springer; 1999
   Google Scholar
• Fukushige S, Matsubara K, Yoshida M, Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6(3):955-8
   PubMed Web of Science ®Google Scholar
• Hattori Y, Odagiri H, Nakatani H, K-sam, an amplified gene in stomach cancer is a member of the heparin-binding growth factor receptor genes. Proc Natl Sci 1990;87(15):5983-7
   PubMed Web of Science ®Google Scholar
• Barranco SC, Townsend CM Jr, Casarteli C, Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res 1983;43:1703-9
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19(9):1523-9
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT, Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8
   PubMed Web of Science ®Google Scholar
• Matsui Y, Inomata M, Tojigamori M, Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005;27:681-5
   PubMed Web of Science ®Google Scholar
• Stoner G, Gupta A. Eitiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001;22(11):1737-1746
   PubMed Web of Science ®Google Scholar
• Stoner GD, Wang LS, Chen T. Chemoprevention of esophageal squamous cell carcinoma. Toxicol Appl Pharmacol 2007;224(3):337-349
   PubMed Web of Science ®Google Scholar
• Beer DG, Stoner GD. Clinical models of chemoprevention for the esophagus. Hematol Oncol Clin N Am 1998;23:1055-77
   Google Scholar
• Liu X, Li P, Zhang ST, COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis Esophagus 2008;21(1):9-14
   PubMed Web of Science ®Google Scholar
• Limburg PJ, Wei W, Ahnen DJ, Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005;129(3):863-73
   PubMed Web of Science ®Google Scholar
• Limburg PJ, Wei W, Ahnen DJ, Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005;129(3):863-73
   PubMed Web of Science ®Google Scholar
• Estensen RD, Anderson WR, Galbraith AR, A method of producing carcinoma in upper aerodigestive tree and esophagus of the Syrian golden hamster using wounding and instillation of n-methylnitrosurea. Cancer Epidemiol Biomarkers Prev 2007;16(8):1644-50
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Yasui Y, Kim M, A novel rasH2 mouse carcinogenesis model that is highly susceptible to 4-NQO-induced tongue and esophageal carcinogenesis is useful for preclinical chemoprevention studies. Carcinogenesis 2008;29(2):418-26
   PubMed Web of Science ®Google Scholar
• Opitz OG, Harada H, Suliman Y, A mouse model of human oral-esophageal cancer. J Clin Invest 2002;110:761-9
   Google Scholar
• Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999;18:7644-55
   PubMed Web of Science ®Google Scholar
• Rustgi AK. Models of esophageal carcinogenesis. Semin Oncol 2006;33(Suppl 11):S57-58
   PubMedGoogle Scholar
• Fong LYY, Lau KM, Huebner K, Magee PN. Induction of esophageal tumors in zinc-deficient rats by single low-doses of N-nitrosmethylbenzylamine (NMBA): analysis of cell proliferation and mutations in H-ras and p53 genes. Carcinogenesis 1997;18:1447-84
   Google Scholar
• Fong LYY, Magee PN. Dietary zinc deficiency enhances esophageal cell proliferation and N-nitrosmethylbenzylamine (NMBA)-induced esophageal tumor incidence in C57BL/6 mouse. Cancer Lett 1999;143:63-9
   PubMed Web of Science ®Google Scholar
• Fong LYY, Mancni R, Nakagwa H, Combined cyclin d1 overexpression and zinc deficiency disrupts cell cycle and accelerates mouse forestomach carcinogenesis. Cancer Res 2003;63:4244-52
   PubMed Web of Science ®Google Scholar
• Fong LY, Jiang Y, Farber JL. Zinc deficiency potentiates induction and progression of lingual and esophageal tumors in p53-deficient mice. Carcinogenesis 2006;27:1489-96
   PubMed Web of Science ®Google Scholar
• Fong LY, Hguyen VT, Faber JL. Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J Natl Cancer Inst 2001;93:1525-33
   PubMed Web of Science ®Google Scholar
• Qiao YL, Sanford M, Dawsey FK, Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the linxian general population nutrition intervention trial. JNCI 2009;101:507-18
   PubMed Web of Science ®Google Scholar
• Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90
   PubMed Web of Science ®Google Scholar
• Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002;346:836-42
   PubMed Web of Science ®Google Scholar
• Corley DA, Levin TR, Habel LA, Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40
   PubMed Web of Science ®Google Scholar
• Buttar NS, Wang KK, Leontocich O, Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in animal model of Barrett's esophagus. Gastroenterology 2002;122(4):1101-12
   PubMed Web of Science ®Google Scholar
• Chen X, Yang G, Ding WY, An esophagogastroduodenal anastamosis model for esophageal adenocarcinoma in rates and enhancement by iron overload. Carcinogenesis 1999;20:1801-8
   PubMed Web of Science ®Google Scholar
• Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT tial. Recent Results Cancer Res 2009;181:161-9
   PubMedGoogle Scholar
• Subramanium D, Ramalingam S, May R, Gastrin mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. Gastroenterology 2008;134:1070-82
   PubMed Web of Science ®Google Scholar
• Obszynka J, Atherfold PA, Nanji M, Long term proton pump induced herpergastrinaemia does induce lineage-specific restitution but no clonal expansion in benign Barrett's Esophagus in vivo. Gut 2009 [Epub ahead of print]
   Web of Science ®Google Scholar
• Attwood SE, Smyrk TC, DeMeester TR, Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats. Surgery 1992;111:503-10
   PubMed Web of Science ®Google Scholar
• Duncan MD, Tihan TT, Donovan DM, Esophagogastric adenocarcinoma in an E1A/E1B transgenic model involves p53 disruption. J Gatrointestinal Surg 2000;4(3)290-297
   PubMed Web of Science ®Google Scholar
• Fein M, Peters JH, Baril N, Loss of function of Trp53, but not Apc, leads to the development of esophageal adenocarcinoma in mice with jejunoesophageal reflux. J Surg Res 1999;83:48-55
   PubMed Web of Science ®Google Scholar
• Hao J, Liu B, Yang CS, Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice. BMC Gastroenterology 2009;9:59-66
   PubMedGoogle Scholar
• Ellis FH Jr, Xu X, Kulke MH. Malignant transformation of the esophageal mucosa is enhanced in p27 knockout mice. J Thorac Cardovac Surg 2001;112:809-14
   Google Scholar
• Pritchard DM, Prezmeck SM. How useful are the rodent animal models of gastric adenocarcinoma? Aliment Pharmacol Ther 2004;19:841-59
   PubMed Web of Science ®Google Scholar
• Honda S, Fujioka T, Tokieda M, Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils. Cancer Res 1998;58:4255-9
   PubMed Web of Science ®Google Scholar
• Fox JG, Sheppard BJ, Dangler CA, Germ-line p53-targeted disruption inhibits Helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res 2002;62:696-702
   PubMed Web of Science ®Google Scholar
• Takaishi S, Okumura T, Wang TC. Gastric cancer stem cells. J Clin Oncol 2008;26:2876-82
   PubMed Web of Science ®Google Scholar
• Houghton J, Stoicov C, Nomura S, Gastric cancer originating from bone marrow derived cells. Science 2004;306:1568-71
   PubMed Web of Science ®Google Scholar
• Wang TC, Dangler CA, Chen D, Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000;118(1):36-47
   PubMed Web of Science ®Google Scholar
• Almedia R, Silva E, Santos-Silva F, Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003;199:36-40
   PubMed Web of Science ®Google Scholar
• Mutoh H, Sakurai S, Satoh K, Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 2004;53:1416-1423
   PubMed Web of Science ®Google Scholar
• Souza RF, Krishnan K, Spechler SJ. Acid, bile and CDX: the ABC of making Barrett's metaplasia. Am J Gastrointest Liver Pysiol 2008;295:211-8
   PubMed Web of Science ®Google Scholar
• Tamano S, Jakubczak J, Takagi H, Increased susceptibility to N-nitrosomethylurea gastric carcinogenesis by transforming growth factor alpha transgenic mice with gastric hyperplasia. Jpn J Cancer Res 1995;86:435-43
   PubMedGoogle Scholar
• Lefebvre O, Chenard MP, Lasson R, Gastric mucosa abnormalities and tumourigenesis in mice lacking the pS2 trefoil protein. Science 1996;274:259-62
   PubMed Web of Science ®Google Scholar
• Judd LM, Alderman BM, Howlett M, Gastric cancer development mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gatroenterology 2004;126:196-207
   PubMed Web of Science ®Google Scholar
• Ernst M, Najdovska M, Grail D, SAT3 and SAT1 mediate IL-11-dependent and inflammation-associated gastric tumourigenesis in gp130 receptor mutant mice. J Clin Invest 2008;118:1727-38
   PubMed Web of Science ®Google Scholar
• Fox JG, Dangler CA, Whary MT, Mice carrying a truncated Apc gene have diminished gastric epithelial proliferation, gastric inflammation and humoral immunity in response to Helicobacter felis infection. Cancer Res 1997;57:3972-8
   PubMed Web of Science ®Google Scholar
• Suzuki H, Miyazawa M, Kai A, No difference in the level of gastric mucosal cell apoptosis and proliferation in Helicobacter pylori-colonized p53 heterozygous knockout mice. Aliment Pharmacol Ther 2002;16(Suppl 2):158-66
   PubMedGoogle Scholar
• Li QL, Ito K, Sakakura C, Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24
   PubMed Web of Science ®Google Scholar
• Xu X, Brodie SG, Yang X, Hapoid loss of the tumour suppressor gene Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 2000;19:1868-74
   PubMed Web of Science ®Google Scholar
• Yokozaki, H. Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathology International 2000;50:767-77
   PubMed Web of Science ®Google Scholar